With GSK and other partners, TAMUS also will utilize CIADM capabilities to develop and transition platform technologies to accelerate new treatments for conditions as diverse as cancer and cardiovascular disease.
Patricia Haigwood 979-458-6052 email@example.com
GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit http://us.gsk.com/
 *EB66® exclusively licensed from Vivalis by GSK Biologicals S.A. for the field of Influenza and sublicensed use at the Texas A&M Center for Innovation in Advanced Development and Manufacturing (CIADM).SOURCE GlaxoSmithKline